On May 3, 2023 Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended March 31, 2023 (Press release, Adaptive Biotechnologies, MAY 3, 2023, View Source [SID1234630899]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We started the year strong with clonoSEQ test volume growth of 57% in the first quarter versus the same period in the prior year," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "We are on track to deliver on our annual goals in both MRD and Immune Medicine and remain committed to drive operational efficiencies while managing capital allocation to support growth."
Recent Highlights
•
Revenue of $37.6 million for the first quarter 2023, representing a 3% decrease from $38.6 million in the first quarter 2022, which reflects the expected $3.2 million decline in amortization of the Genentech upfront payment.
•
clonoSEQ test volume increased 57% to 12,079 tests delivered in the first quarter 2023, compared to the first quarter of prior year.
•
Signed a new translational pan-portfolio collaboration with Takeda for the use of clonoSEQ to measure MRD as a clinical endpoint.
•
Immune Medicine generated $16.2 million in revenue during the first quarter 2023 from two distinct areas (Pharma Services and Drug Discovery), representing 43% of total first quarter revenue.
•
Announced the consolidation of the President and Chief Operating Officer roles under Julie Rubinstein.
First Quarter 2023 Financial Results
Revenue was $37.6 million for the quarter ended March 31, 2023, representing a 3% decrease from the first quarter in the prior year. Immune Medicine revenue was $16.2 million for the quarter, representing a 22% decrease from the first quarter in the prior year mainly driven by a decline in amortization of the Genentech upfront payment. MRD revenue was $21.4 million for the quarter, representing a 20% increase from the first quarter in the prior year.
Operating expenses were $94.8 million for the first quarter of 2023, compared to $101.7 million in the first quarter of the prior year, representing a decrease of 7%. Interest expense from our revenue interest purchase agreement was $3.5 million in the first quarter of 2023.
Net loss was $57.7 million for the first quarter of 2023, compared to $62.8 million for the same period in 2022.
Adjusted EBITDA (non-GAAP) was a loss of $37.1 million for the first quarter of 2023, compared to a loss of $43.1 million for the first quarter of the prior year.
Cash, cash equivalents and marketable securities was $440.7 million as of March 31, 2023.
2023 Financial Guidance
Adaptive Biotechnologies reiterates full year 2023 revenue to be in the range of $205 million to $215 million. We continue to expect operating expenses, including cost of revenue, to be below full year 2022 operating expenses of $385.5 million.
Webcast and Conference Call Information
Adaptive Biotechnologies will host a conference call to discuss its first quarter 2023 financial results after market close on Wednesday, May 3, 2023 at 4:30 PM Eastern Time. The conference call can be accessed at View Source The webcast will be archived and available for replay at least 90 days after the event.